Retatrutide (LY-3437943) is an investigational drug developed by Eli Lilly that acts as a triple hormone receptor agonist : GLP-1 (glucagon-like peptide-1) receptor agonist GIP (glucose-dependent insulinotropic polypeptide) receptor agonist Glucagon receptor agonist - read about why this is so important here This triagonist approach amplifies the metabolic impact seen with GLP-1 and GIP combinations like tirzepatide, while also leveraging glucagons thermogenic and energy-expending properties
Load more Close Code Verified by our community Get 25% Off Lose Weight Quiz (Promo Code) Details 11 verifications Offer's Details: Save 25% on your purchase with this special Noom discount
However, because the studies differed considerably in how they measured these behaviors and the types of participants they enrolled, the authors caution that the pooled estimate should be interpreted carefully
This attribute underscores retatrutides potential in exploring treatments for metabolic syndrome and related conditions
We are looking at very specific metabolic markers
As with all chronic diseases, it would be much more profitable to prevent obesity than to cure it by attacking the causes of this overweight as a priority, rather than devoting all our efforts and financial means to their treatment
